SAB Biotherapeutics (SABS) Other Gross PP&E Adjustments (2020 - 2025)
SAB Biotherapeutics (SABS) has disclosed Other Gross PP&E Adjustments for 6 consecutive years, with $24.2 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Other Gross PP&E Adjustments fell 7.19% year-over-year to $24.2 million, compared with a TTM value of $24.2 million through Dec 2025, down 7.19%, and an annual FY2025 reading of $24.2 million, down 7.19% over the prior year.
- Other Gross PP&E Adjustments was $24.2 million for Q4 2025 at SAB Biotherapeutics, down from $27.1 million in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at $29.1 million in Q3 2023 and bottomed at -$1.5 million in Q1 2022.
- Average Other Gross PP&E Adjustments over 5 years is $22.6 million, with a median of $26.4 million recorded in 2025.
- Peak annual rise in Other Gross PP&E Adjustments hit 1823.42% in 2023, while the deepest fall reached 10.58% in 2023.
- Year by year, Other Gross PP&E Adjustments stood at $3.0 million in 2021, then surged by 769.52% to $26.5 million in 2022, then fell by 10.58% to $23.7 million in 2023, then grew by 10.1% to $26.1 million in 2024, then fell by 7.19% to $24.2 million in 2025.
- Business Quant data shows Other Gross PP&E Adjustments for SABS at $24.2 million in Q4 2025, $27.1 million in Q3 2025, and $26.9 million in Q2 2025.